Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Biol Chem ; 289(26): 18514-25, 2014 Jun 27.
Article in English | MEDLINE | ID: mdl-24828503

ABSTRACT

FBXO31 was originally identified as a putative tumor suppressor gene in breast, ovarian, hepatocellular, and prostate cancers. By screening a set of cell cycle-regulated proteins as potential FBXO31 interaction partners, we have now identified Cdt1 as a novel substrate. Cdt1 DNA replication licensing factor is part of the pre-replication complex and essential for the maintenance of genomic integrity. We show that FBXO31 specifically interacts with Cdt1 and regulates its abundance by ubiquitylation leading to subsequent degradation. We also show that Cdt1 regulation by FBXO31 is limited to the G2 phase of the cell cycle and is independent of the pathways previously described for Cdt1 proteolysis in S and G2 phase. FBXO31 targeting of Cdt1 is mediated through the N terminus of Cdt1, a region previously shown to be responsible for its cell cycle regulation. Finally, we show that Cdt1 stabilization due to FBXO31 depletion results in re-replication. Our data present an additional pathway that contributes to the FBXO31 function as a tumor suppressor.


Subject(s)
Cell Cycle Proteins/metabolism , DNA Replication , F-Box Proteins/metabolism , Tumor Suppressor Proteins/metabolism , Cell Cycle , Cell Cycle Proteins/genetics , F-Box Proteins/genetics , G2 Phase , Humans , Protein Binding , Proteolysis , Tumor Suppressor Proteins/genetics , Ubiquitination
2.
Oncotarget ; 2(12): 1203-17, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22203497

ABSTRACT

Mutations in the TP53 gene commonly result in the expression of a full-length protein that drives cancer cell invasion and metastasis. Herein, we have deciphered the global landscape of transcriptional regulation by mutant p53 through the application of a panel of isogenic H1299 derivatives with inducible expression of several common cancer-associated p53 mutants. We found that the ability of mutant p53 to alter the transcriptional profile of cancer cells is remarkably conserved across different p53 mutants. The mutant p53 transcriptional landscape was nested within a small subset of wild-type p53 responsive genes, suggesting that the oncogenic properties of mutant p53 are conferred by retaining its ability to regulate a defined set of p53 target genes. These mutant p53 target genes were shown to converge upon a p63 signalling axis. Both mutant p53 and wild-type p63 were co-recruited to the promoters of these target genes, thus providing a molecular basis for their selective regulation by mutant p53. We demonstrate that mutant p53 manipulates the gene expression pattern of cancer cells to facilitate invasion through the release of a pro-invasive secretome into the tumor microenvironment. Collectively, this study provides mechanistic insight into the complex nature of transcriptional regulation by mutant p53 and implicates a role for tumor-derived p53 mutations in the manipulation of the cancer cell secretome.


Subject(s)
Gene Expression Regulation, Neoplastic , Transcription Factors/metabolism , Transcriptional Activation/genetics , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/metabolism , Cell Cycle/genetics , Cell Line, Tumor , Cell Proliferation , Humans , Neoplasm Invasiveness/genetics , Signal Transduction , Transcription Factors/genetics , Transcription, Genetic , Transcriptome , Tumor Microenvironment/genetics , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Proteins/genetics
3.
J Cell Biochem ; 112(10): 2742-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21678463

ABSTRACT

A significant proportion of transcription factors encoded by the human genome are classical C(2) H(2) zinc finger proteins that regulate gene expression by directly interacting with their cognate DNA binding motifs. We previously showed that one such C(2) H(2) zinc finger DNA binding protein, ZNF652 (zinc finger protein 652), specifically and functionally interacts with CBFA2T3 to repress transcription of genes involved in breast oncogenesis. To identify potential targets by which ZNF652 exerts its putative tumour suppressive function, its promoter-specific cistrome was mapped by ChIP-chip. De novo motif scanning of the ZNF652 binding sites identified a novel ZNF652 recognition motif that closely resembles the previously characterised in vitro binding site, being a 10 nucleotide core of that 13 nucleotide sequence. Genes with ZNF652 binding sites function in diverse cellular pathways, and many are involved in cancer development and progression. Characterisation of the in vivo ZNF652 DNA binding motif and identification of potential ZNF652 target genes are key steps towards elucidating the function(s) of this transcription factor in the normal and malignant breast cell.


Subject(s)
Breast Neoplasms/genetics , Chromosome Mapping/methods , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Promoter Regions, Genetic/genetics , Binding Sites/genetics , Cell Line, Tumor , Chromatin/metabolism , Chromatin Immunoprecipitation , Humans , Hydro-Lyases/metabolism , Polymerase Chain Reaction , Protein Binding , Repressor Proteins/metabolism , Transcription Factors/metabolism , Tumor Suppressor Proteins/metabolism
4.
FEBS Lett ; 584(5): 859-64, 2010 Mar 05.
Article in English | MEDLINE | ID: mdl-20116376

ABSTRACT

A significant proportion of the human genome codes for transcription factors. Balanced activity of transcriptional activators and repressors is essential for normal development and differentiation. Previously we reported that a classical C2H2 zinc finger DNA binding protein ZNF652 functionally interacts with CBFA2T3 to repress transcription of genes containing ZNF652 consensus DNA binding sequence within the promoters of these target genes. Here we show that ZNF651 is a ZNF652 paralogue that shares a common DNA binding sequence with ZNF652 and represses target gene expression through the formation of a CBFA2T3-ZNF651 corepressor complex. It is suggested that CBFA2T3-ZNF651 and CBFA2T3-ZNF652 repressor complexes perform functionally similar roles in a tissue-specific manner.


Subject(s)
DNA-Binding Proteins/metabolism , Phosphoproteins/metabolism , Repressor Proteins/metabolism , Tumor Suppressor Proteins/metabolism , Amino Acid Sequence , Base Sequence , Blotting, Western , Cell Line , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/genetics , Electrophoretic Mobility Shift Assay , HeLa Cells , Humans , Immunoprecipitation , Molecular Sequence Data , Phosphoproteins/chemistry , Phosphoproteins/genetics , Protein Binding , Repressor Proteins/chemistry , Repressor Proteins/genetics , Sequence Homology, Amino Acid , Tumor Suppressor Proteins/chemistry , Tumor Suppressor Proteins/genetics
5.
J Cell Sci ; 121(Pt 21): 3541-52, 2008 Nov 01.
Article in English | MEDLINE | ID: mdl-18840648

ABSTRACT

The ability of p53 to act as a transcription factor is critical for its function as a tumor suppressor. Ankyrin repeat domain 11, ANKRD11 (also known as ANR11 or ANCO1), was found to be a novel p53-interacting protein that enhanced the transcriptional activity of p53. ANKRD11 expression was shown to be downregulated in breast cancer cell lines. Restoration of ANKRD11 expression in MCF-7 (wild-type p53) and MDA-MB-468 (p53(R273H) mutant) cells suppressed their proliferative and clonogenic properties through enhancement of CDKN1A (p21(waf1)/CIP1) expression. ShRNA-mediated silencing of ANKRD11 expression reduced the ability of p53 to activate CDKN1A expression. ANKRD11 was shown to associate with the p53 acetyltransferases and cofactors, P/CAF and hADA3. Exogenous ANKRD11 expression enhanced the levels of acetylated p53 in both MCF-7 and MDA-MB-468 cells. ANKRD11 enhanced the DNA-binding properties of mutant p53(R273H) to the CDKN1A promoter, suggesting that ANKRD11 can mediate the restoration of normal p53 function in some cancer-related p53 mutations. In addition, ANKRD11 itself was found to be a novel p53 target gene. These findings demonstrate a role for ANKRD11 as a p53 coactivator and suggest the involvement of ANKRD11 in a regulatory feedback loop with p53.


Subject(s)
Gene Expression Regulation, Neoplastic , Promoter Regions, Genetic , Repressor Proteins/metabolism , Tumor Suppressor Protein p53/metabolism , Breast Neoplasms/metabolism , Cell Line, Tumor , DNA/chemistry , Gene Silencing , Genes, p53 , HeLa Cells , Humans , Models, Biological , Mutation , Protein Structure, Tertiary , Transcription, Genetic
6.
J Biol Chem ; 283(27): 19026-38, 2008 Jul 04.
Article in English | MEDLINE | ID: mdl-18456661

ABSTRACT

Transcriptional repression plays a critical role in development and homeostasis. The ETO family represents a group of highly conserved and ubiquitously expressed transcriptional regulatory proteins that are components of a diverse range of multiprotein repressor complexes. ETO proteins function as transcriptional repressors by interacting with a number of transcription factors that bind to their cognate consensus DNA binding sequences within the promoters of target genes. We previously reported that the classical C(2)H(2) zinc finger DNA-binding protein, ZNF652, specifically and functionally interacts with the ETO protein CBFA2T3 and has a role in the suppression of breast oncogenesis. Here we report the identification and validation of the ZNF652 consensus DNA binding sequence. Our results show that the E-box gene HEB is a direct target of CBFA2T3-ZNF652-mediated transcriptional repression. The CBFA2T3-ZNF652 complex regulates HEB expression by binding to a single ZNF652 response element located within the promoter sequence of HEB. This study also shows that the NHR3 and NHR4 domains of CBFA2T3 interact with a conserved proline-rich region located within the C terminus of ZNF652. Our results, together with previous reports, indicate that HEB has a complex relationship with CBFA2T3; CBFA2T3 interacts with ZNF652 to repress HEB expression, and in addition CBFA2T3 interacts with the HEB protein to inhibit its activator function. These findings suggest that CBFA2T3-ZNF652-mediated HEB regulation may play an important role in hematopoiesis and myogenesis.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/biosynthesis , Breast Neoplasms/metabolism , Cell Transformation, Neoplastic/metabolism , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Neoplastic , Multiprotein Complexes/metabolism , Phosphoproteins/metabolism , Repressor Proteins/metabolism , Transcription, Genetic , Tumor Suppressor Proteins/metabolism , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Breast Neoplasms/genetics , CHO Cells , Cell Transformation, Neoplastic/genetics , Cricetinae , Cricetulus , DNA-Binding Proteins/genetics , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Jurkat Cells , Multiprotein Complexes/genetics , Phosphoproteins/genetics , Protein Structure, Tertiary/physiology , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , RUNX1 Translocation Partner 1 Protein , Repressor Proteins/genetics , Response Elements/genetics , Transcription Factors/genetics , Transcription Factors/metabolism , Transcription, Genetic/genetics , Tumor Suppressor Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL